Key result
Sleeve gastrectomy and RYGB reduce body weight versus sham in obese MASLD mice.
Why the study?
Research on mouse metabolic and bariatric surgery models remains limited due to small size and surgical complexity, necessitating optimized techniques to establish reliable models for mechanistic research.
Absolute Event Rate: 40.84% vs 29.54%
p-value: p=<0.001
Sleeve gastrectomy and modified Roux-en-Y gastric bypass can be successfully established in a mouse model of obesity with MASLD, leading to significant improvements in weight and metabolic parameters.
Advances mouse MBS models for mechanistic studies; leaves open translation to human metabolic surgery.
Obesity and related metabolic diseases are major global health challenges. Metabolic and bariatric surgery (MBS) is an effective treatment. Yet exploring its molecular mechanisms remains limite due to the challenge of obtaining postoperative tissue samples. While rat models are more convenient in size and operation, mouse models offer unique advantages such as lower breeding costs and easier genetic modification. However, research on mouse MBS models is still limited because of their small size and surgical complexity, highlighting the need for optimized techniques to advance the field. This study aims to establish a high-fat diet-induced (HFD) obesity combined with metabolic dysfunction-associated steatotic liver disease (MASLD) mouse model, and to evaluate the MBS models assisted by microsurgery, so as to provide a reliable tool for mechanism research. Male SPF C57BL/6J mice were randomly assigned to the normal diet (ND) group and the HFD group. The mouse in the HFD group were induced to develop obesity with MASLD through a high-fat diet for 16 weeks. The HFD group was further divided into sham operation group (Sham), sleeve gastrectomy (SG) group, and modified Roux-en-Y gastric bypass (RYGB) group (n = 6). Metabolic efficacy was evaluated by weight, metabolic parameters, and pathological staining analysis at the 4th week post-surgery. Compared with the ND group, the weight of the HFD group increased by 38.25% (P < 0.001), and the liver tissue showed pathological features of MASLD. Compared with the Sham group, the weight of the SG group and the modified RYGB group decreased significantly at 4 weeks after operation (P < 0.05). Compared with the Sham group, the insulin sensitivity of the RYGB group was improved. Hepatic steatosis was significantly reduced in SG and RYGB groups, and serum TG and LDL levels were significantly improved. The postoperative survival rate of SG and Sham mice was 100%, and RYGB was 83.3% (1 case died of anastomotic stenosis). The establishment of a modified RYGB and SG mouse model has good reproducibility, safety, and efficacy. This study provides a useful tool for exploring the mechanism of MBS in the treatment of obesity with MASLD. • SG was successfully established in a mouse model of obesity with MASLD. • Modified RYGB was successfully established in a mouse model of obesity with MASLD. • Postoperative metabolic indices verified the stability and reliability of the model.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Obesity and MASLD (n=30). Sleeve gastrectomy and modified Roux-en-Y gastric bypass vs. Sham operation was evaluated on Body weight after 16 weeks of high-fat diet induction (HFD vs ND) (p=<0.001). Sleeve gastrectomy and modified Roux-en-Y gastric bypass significantly decreased body weight at 4 weeks post-operation compared to sham surgery in a mouse model of obesity and MASLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: